Long-term efficacy, safety, and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two-year results from a Phase III double-blind, randomised controlled trial.

Dorota Maria KrasowskaT GambichlerC CortesAmir HorevN CompagnoS S DahaleP PapanastasiouD Keefe

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Secukinumab demonstrated sustained long-term efficacy (up to 2 years) and a favourable safety profile (~320 PY of treatment) in paediatric patients with severe chronic plaque psoriasis.

Keyphrases

phase iii
double blind
open label
placebo controlled
clinical trial
study protocol
ankylosing spondylitis
coronary artery disease
phase ii
drug induced
intensive care unit
early onset
emergency department
randomized controlled trial
rheumatoid arthritis